Format

Send to

Choose Destination
Cancer Lett. 2019 Aug 10;457:40-46. doi: 10.1016/j.canlet.2019.05.004. Epub 2019 May 9.

Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.

Author information

1
Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA; Department of Pathology, University of California, San Diego, La Jolla, CA, 92093, USA.
2
Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA; Department of Pathology, University of California, San Diego, La Jolla, CA, 92093, USA. Electronic address: jdesgrosellier@ucsd.edu.

Abstract

Breast cancer cells with stem cell properties play an important role in tumor progression and thus are key targets for therapy. Here, we show that combined Bcl-2/Src inhibition synergize to deplete stem-like cells. While Src inhibition increases pro-apoptotic PUMA, we find that a significant amount interacts with Bcl-2 and Bcl-xL, promoting resistance to cell death. Consistent with this, the clinically-approved Bcl-2 selective drug venetoclax was sufficient to overcome resistance by preventing PUMA/Bcl-2 binding, enhancing apoptosis. This effect was specific to stem-like breast cancer cells as there was no effect on luminal or basal-like cell types. In contrast, the Mcl-1 inhibitor S63845 potently targeted basal-like, but not stem-like cells, highlighting dependency on distinct sentinel Bcl-2 family members. Our findings reveal Bcl-2/Src inhibition as a superior therapy to target stemness, providing a foundation for a potential personalized strategy to reduce breast cancer progression.

KEYWORDS:

Breast cancer; Cancer stem cell; PUMA; Therapeutic resistance; Venetoclax

PMID:
31078737
DOI:
10.1016/j.canlet.2019.05.004
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center